Traduction de «advice » (Néerlandais → Français) :

Brief advice only Brief advice+NRT Brief advice+bupropion Brief advice+NRT+bupropion Counselling only Counselling+NRT Counselling+bupropion Counselling+NRT+bupropion
Brief advice only Brief advice+NRT Brief advice+Buproprion Brief advice+NRT+Buproprion Counselling only Counselling+NRT Counselling+Buproprion Counselling+NRT+Buproprion

Decision analytic model (time horizon 1 year) US Payer (third party payer or patient) Pharmacist advice alone Pharmacist advice+NRT patch Pharmacist advice+NRT gum Pharmacist advice+bupropion Study funded by an American Pharmaceutical Association Foundation Incentive Grant
Decision analytic model (time horizon 1 year) US Payer (third party payer or patient) Pharmacist advice alone Pharmacist advice+NRT patch Pharmacist advice+NRT gum Pharmacist advice+Buproprion Study funded by an American Pharmaceutical Association Foundation Incentive Grant

Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.

Decision analytic model UK NHS Brief advice+NRT Brief advice+bupropion Brief advice+NRT+bupropion Counselling+NRT Counselling+bupropion Counselling+NRT+bupropion None
Decision analytic model UK NHS Brief advice+NRT Brief advice+Bupropion Brief advice+NRT+Buproprion Counselling+NRT Counselling+Buproprion Counselling+NRT+Buproprion None

20. Coleman T,.Wilson A. Anti-smoking advice from general practitioners: is a population-based approach to advice-giving feasible?
20. Coleman T, Wilson A. Anti-smoking advice from general practitioners: is a population-based approach to advice-giving feasible?

Scientific advice regarding vaccines for veterinary use is almost exclusively dealt with at a European level by the Scientific Advice Working Party-Veterinary (SAWP-V).
Scientific advice regarding vaccines for veterinary use is almost exclusively dealt with at a European level by the Scientific Advice Working Party-Veterinary (SAWP-V).

narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September
narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September

Estimated cost of bupropion is similar to the estimated cost of NRT GP advice can be opportunistic, i.e. given during a consultation primarily concerned with another health matter.
Estimated cost of Buproprion is similar to the estimated cost of NRT GP advice can be opportunistic, i.e. given during a consultation primarily concerned with another health matter.

Tijdens een CHMP-PDCO-SAWP (Sientific Advice Working Party) break-outsessie werd de aard van de gegevens die kunnen geëxtrapoleerd worden van het gebruik van geneesmiddelen bij volwassenen of van andere producten uit dezelfde farmacologische klasse besproken.
Lors d’une break-out session CHMP-PDCO-SAWP (Scientific Advice Working Party), la nature des données qui peuvent être extrapolées à partir de l’utilisation de médicaments chez les adultes ou à partir d’autres produits de la même classe pharmacologique a été discutée.

De CLEAR (Common Language Evidence-based Advices and Recommendations) publicaties van het KCE bevatten de wetenschappelijke adviezen van een KCE rapport, vertaald naar een verstaanbare taal.
Les publications KCE CLEAR (Common Language Evidence-based Advices and Recommendations) contiennent les conseils scientifiques issus de rapports KCE, traduits dans un langage courant.